TerraBioGen Technologies closes $576K private placement

TerraBioGen Technologies Inc.



News Release

TerraBioGen Closes Private Placement

Vancouver, Canada, October 20, 2017 – TerraBioGen Technologies Inc., a developer of proprietary high-value agriculturally bioactive products, announces that it has closed a private placement.
The private placement is for 192,000 units at $3.00 per unit for proceeds of $576,000. Each unit consists of one common share and one warrant exercisable at $5.00 per common share for 5 years.
These funds will be used to purchase pilot line formulation equipment, and continue the company’s internal research and development. The funds will also be used to continue collaboration with its university and institutional partners, and further commercialization through specific, cooperative field trials.

About TerraBioGen

TerraBioGen Technologies Inc. is a developer of innovative, proprietary, high-value, environmentally sustainable bioproducts and biostimulants that improve crop health and yields, and increase abiotic and biotic stress tolerance in agricultural and horticultural crops. The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Further, the Company is taking steps to secure intellectual property rights to these bioproducts and to formulate them in order to fully commercialize their potential.

For more information, please contact:

Blair Heffelfinger
President & CEO
TerraBioGen Technologies Inc.
bheffelfinger@terrabiogen.com
(604) 444-1023 ext 316
(604) 444-1043 fax

Bob Nowell
CFO & Corporate Secretary
TerraBioGen Technologies Inc.
bnowell@terrabiogen.com
(604) 444-1023 ext 306
(604) 444-1043 fax